Criteria to be considered for the evaluation of new active substance (NAS) status of biological substances
Table of contents
This reflection paper is intended to reflect the current experience of the Biologics Working Party (BWP) of the Committee for Medicinal Products for Human Use (CHMP), the Committee for Advanced Therapies (CAT), and the Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh) on New Active Substance (NAS) in the context of scientific advice and assessment of Marketing Authorisation Applications (MAA).
It applies to all types of procedures for submission of a MAA, i.e. Centralised Procedure (CP), Mutual Recognition Procedure (MRP)/Decentralised Procedure (DCP) and purely national procedures for biological and biotechnology-derived medicinal products for human use.
Keywords: New active substance, NAS, biologic, ATMPs, notice to applicants